Filler

Drug point

Topical choline salicylates implicated in Reye’s syndrome

BMJ 2008; 336 doi: 10.1136/bmj.39462.656736.AD (Published 12 June 2008)
Cite this as: BMJ 2008;336:1376

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. T K Oman, senior house officer12,
  2. M C Stewart, senior lecturer2,
  3. A Burns, pharmacist3,
  4. T F Lang, principal biochemist4
  1. 1Royal Belfast Hospital for Sick Children, Belfast BT12 6BE
  2. 2Department of Child Health, Queen’s University of Belfast, Belfast
  3. 3Pharmacy Department, The Royal Group Hospitals Belfast, Belfast
  4. 4Clinical Biochemistry Department, The Royal Group Hospitals Belfast
  1. Correspondence to: T K Oman tudorandlucy{at}gmail.com
  • Accepted 1 October 2007

Salicylate use in children was implicated in the development of Reye’s syndrome.1 After the recommendation in the 1980s that preparations containing aspirin should not be given to children unless specifically indicated, Reye’s syndrome has almost disappeared from clinical practice.2 The Medicines and Health products Regulatory Agency (MHRA) states that only systemically absorbed acetylsalicylates are associated with Reye’s syndrome.

A 20 month old …

Access to the full text of this article requires a subscription or payment

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Rapid responses

THIS WEEK'S POLL

BMJ most popular